Lead clinical candidate CTX-187 is a novel antimicrobial immunotherapy developed to treat clinically-prevalent and multi-drug resistant Gram-negative bacterial infections -- Qualified Infectious ...
CARB-X announced today that it’s awarding $1.2 million to a research team at Harvard University to develop enhanced antibiotics for multidrug-resistant bacteria.
Abstract and Introduction Empirical Antimicrobial Therapy Against Gram-negative Pathogens Adverse Consequences Related to Combination Antimicrobial Use Conclusion References A recent retrospective ...
Researchers report that photodynamic therapy increases antibiotic penetration and disrupts resistance mechanisms in laboratory strains.
Please provide your email address to receive an email when new articles are posted on . Gram-negative bacteria comprise most of the CDC and WHO’s lists of critical and urgent antibiotic-resistant ...
In a recent study published in the journal Nature, researchers in the United States of America designed and discovered lolamicin, a selective antibiotic that targets the lipoprotein transport system ...
Drugmakers must focus on developing new antibiotics to fight hospital “superbugs” including meningitis and other infections that can resist last-line treatments, the World Health Organization (WHO) ...
BRD is often framed as stress, viruses and bacteria. Managing inflammation tied to endotoxin helps explain why some cattle recover faster than others ...
Lead clinical candidate CTX-187 is a novel antimicrobial immunotherapy developed to treat clinically-prevalent and multi-drug resistant Gram-negative bacterial infections Qualified Infectious Disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results